Latest News

Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Marking a milestone for gene editing

November 2020

We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001

View Article

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 2020

Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)

View Article

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 2020

ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.

View Article

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 2020

Richmond Pharmacology early phase drug development update.

View Article

COVID-19 – External Monitoring Guidelines

July 2020

Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.

View Article

Statement: COVID-19

March 2020

Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.

View Article

Meet the experts

Meet the leadership team and scientific experts behind Richmond Pharmacology's clinical research excellence.

Careers at Richmond

We are on the lookout for people who love what they do, strive for excellence and who want to make a difference.

Our Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Richmond Pharmacology Appoints Dr Daniel Chapple as Commercial Director

July 13, 2026

Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Dr Daniel Chapple PhD FCIM as Commercial Director.

ESC Congress 2026

28 - 31 August 2026

Richmond Pharmacology is pleased to attend the ESC Congress 2026 in Munich, Germany, on 28 - 31 August 2026.

View event

Low data variability

Exceptional ECG generation

Experts in cardiac safety

Our specialist services

サービス一覧

News

Stay up to date with the latest activity at Richmond Pharmacology

Marking a milestone for gene editing

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

Richmond Pharmacology supports ReViral with the development of Sisunatovir

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

COVID-19 – External Monitoring Guidelines

Statement: COVID-19

Meet the experts

Careers at Richmond

Our Videos

Latest news

Richmond Pharmacology Appoints Dr Daniel Chapple as Commercial Director

Upcoming Event

ESC Congress 2026

About us

Knowledge Base

Connect with us